<DOC>
	<DOCNO>NCT00083512</DOCNO>
	<brief_summary>This study collect blood urine sample patient undergo radiation therapy glioblastoma multiforme ( type brain tumor ) investigate effect treatment blood cell certain protein . The information study may help scientist develop new test measure radiation exposure find new way treat cancer radiation , help determine kind patient tumor respond good radiation therapy . Two protein particular interest study may involve recurrence cancer VEGF ( vascular endothelial growth factor ) MMPs ( matrix metalloproteinases ) . Patients 18 year age old glioblastoma multiforme receive receive radiation therapy part medical treatment may eligible study . Candidates screen history physical examination , blood test , magnetic resonance imaging ( MRI ) brain . Participants blood urine sample collect , completion radiation treatment . Urine sample collect cup 2 tablespoon blood withdrawn needle vein . Additional sample may request different time treatment 3-year follow-up period .</brief_summary>
	<brief_title>Collection Blood Urine Samples Patients Receiving Radiation Therapy Glioblastoma Multiforme</brief_title>
	<detailed_description>BACKGROUND - Preliminary data generate pilot protocol 02-C-0064 suggests urinary VEGF MMP level one month follow-up time point compare last on-treatment time point collection may predictive tumor recurrence one year ( l ) . - Note preliminary study include patient histology . - In ongoing effort validate result large homogeneous patient cohort propose prospectively study patient undergo radiotherapy GBM . OBJECTIVES -We determine whether VEGF MMP level measurement aide predict tumor recurrence 1 year . ELIGIBILITY -Patients see radiation oncology clinic ask provide sample blood urine , radiation treatment . DESIGN - This protocol-provides mean acquire blood urine sample patient receive radiation therapy Glioblastoma multiforme ( GBM ) . - Patients stratify accord Radiation Therapy Oncology Group ( RTOG ) recursive partition prognostic subgroup , include patient age , KPS , extent resection neurological function .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>INCLUSION CRITERIA : Age great equal 18 year Histologically confirm supratentorial Glioblastoma multiforme Karnofsky performance great 60 Patient must candidate radiotherapy Ability subject Legally Authorized Representative ( LAR ) understand willingness sign write informed consent document . EXCLUSION CRITERIA : Patients cancer exclude nonmelanomatous skin cancer carcinoma situ Gliadel wafer placement time surgery &lt; TAB &gt; &lt; TAB &gt;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 26, 2016</verification_date>
	<keyword>Blood</keyword>
	<keyword>Urine</keyword>
	<keyword>GBM</keyword>
	<keyword>Radiation</keyword>
	<keyword>Glioblastoma Multiforme</keyword>
</DOC>